Plenary 1: Innovations in liver disease therapy: present and future

• Innovations in direct-acting antiviral therapies
• Innovations in antiviral immunotherapy
• Innovations in liver fibrosis and NASH therapy
• Innovations in hepatocellular carcinoma therapy

Plenary 2: Public health interventions in liver diseases

• Public health tools to eliminate viral hepatitis
• Global achievements and failures in viral hepatitis elimination
• HCV elimination in Egypt: a success story
• Public health interventions to eliminate NAFLD/NASH

Plenary 3: New vaccine approaches for liver diseases

• The story and future of RNA vaccines
• Towards an HCV vaccine
• The future of therapeutic vaccines for viral infections
• Implementing global vaccination strategies

Plenary 4: Global Hepatitis Summit 2023 Debrief

• HCV Debrief
• HBV/HDV Debrief
• NAFLD/NASH Debrief
• HCC Debrief

Basic Parallel 1: HCV/flavivirus virology

• What did HCV teach us on flavivirus virology
• HCV entry: lessons learnt for other viruses

Basic Parallel 2: HCV immunology

• Innate immune responses against HCV
• Adaptive immune responses against HCV

Basic Parallel 3: HBV/HDV virology

• Update on HBV virology
• Update on HDV virology

Basic Parallel 4: HBV/HDV immunology

• Immunological phenotyping of HBV infections
• Liver compartmentalization of anti-HBV immune responses

Basic Parallel 5: HBV/HDV treatment targets

• Targeting HBV capsids for therapy
• Targeting HBV RNAs for therapy

Basic Parallel 6: NASH targets for new therapies

• Molecular targets for NASH therapy
• Preclinical assessment of NASH compounds

Basic Parallel 7: HCC targets for new therapies

• Molecular targets for HCC therapy
• Immunological targets for HCC therapy

Basic Parallel 8: HEV virology and persistence

• Update on HEV virology
• Mechanisms of HEV persistance in immunodepressed patients

Basic Parallel 9: Liver inflammation and fibrogenesis

• Mechanisms of NAFLD/NASH-associated liver inflammation
• Mechanisms of liver fibrogenesis

Clinical Parallel 1: Applications of artificial intelligence in liver disease management

• Artificial intelligence for liver cancer management
• Artificial intelligence for liver fibrosis management

Clinical Parallel 2: Difficult-to-treat HCV patients

• Unusual HCV genotypes/subtypes
• Difficult-to-cure HCV liver diseases

Clinical Parallel 3: New strategies with approved HBV treatments

• Stoppings NUC strategies
• Interferon add-on/switch strategies

Clinical Parallel 4: New HBV drug clinical developments

• Direct-acting antiviral HBV drugs in development
• Anti-HBV immunotherapies and combination perspectives

Clinical Parallel 5: New HDV therapies

• Bulevirtide in HDV therapy
• New treatments in HDV (except bulevirtide)

Clinical Parallel 6: Long-term outcomes of treated patients with viral hepatitis

• Long-term outcomes of treated HBV patients
• Long-term outcomes of cured HCV patients

Clinical Parallel 7: NAFLD/NASH therapeutic developments

• Endpoints in NAFLD/NASH therapeutic developements
• New treatment approaches for NAFLD/NASH

Clinical Parallel 8: Impacts of COVID-19 on liver disease management

• Negative impacts of COVID-19 on liver disease management
• Positive impacts of COVID-19 on liver disease management

Clinical Parallel 9: Hepatocellular carcinoma new drug clinical trials

• HCC new drug clinical trials in Europe and North America
• HCC new drug clinical trials in Asia

Clinical Parallel 10: Viral hepatitis and liver transplantation in 2023

• HCV and liver transplantation: 2023 update
• HBV/HDV and liver transplantation: 2023 update

Clinical Parallel 11: New biomarkers for liver diseases

• New biomarkers for fibrosis assessment
• New biomarkers for HCC risk prediction

Clinical Parallel 12: New developments in liver pathogen detection and discovery

• Metagenomics for pathogen diagnosis and discovery
• Acute severe hepatitis of unknown origin in children

PH Parallel 1: Epidemiology of HCV in resource-limited countries

• Prevalence of HCV infection in resource-limited countries
• Dynamics of the HCV epidemic in resource-limited countries

PH Parallel 2: Global epidemiology of HBV/HDV infections

• Global epidemiology of HBV infection
• Global epidemiology of HDV infection

PH Parallel 3: Viral hepatitis elimination achievements and challenges

• Global viral hepatitis elimination achievements
• Global viral hepatitis elimination challenges

PH Parallel 4: Simplified approaches for screening and diagnosis of viral hepatitis

• Simplified approaches for HCV screening and diagnosis
• Simplified approaches for HBV/HDV screening and diagnosis

PH Parallel 5: Reaching vulnerable populations for viral hepatitis elimination

• Reaching PWID/prison populations for viral hepatitis elimination
• Reaching migrant populations for viral hepatitis elimination

Late-Breaker

ANRS/AFEF: The French model

• The French viral hepatitis program
• The French HBV cure program

Debate Session 1: Public health

• Post-COVID relaunch of HCV testing/treatment
• Improving screening and linkage-to-care in viral hepatitis B and C
• Public health interventions and awareness in NAFLD/NASH
• Engaging policy makers and patient advocacy groups in liver disease

Debate Session 2: Clinical

• Revisiting HBV treatment guidelines: a 2023 update
• Understanding HBV biomarkers, redifining new treatment endpoints
• The path forward in NAFLD/NASH therapeutic developments
• Classification of HCC patients for therapy